Anita K. Kambhampati

Anita K. Kambhampati

Auto-generated profile, based on publicly available information

Anita K. Kambhampati

Viral Gastroenteritis Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NBNeha Balachandran
Neha Balachandran
JCJordan Cates
Jordan Cates
AKAnita K Kambhampati
Anita K Kambhampati
VMVincent C Marconi
Vincent C Marconi
AWAlexis Whitmire
Alexis Whitmire
SMSara A Mirza
Sara A Mirza
Background: In the United States, ∼179 million acute gastroenteritis (AGE) episodes occur annually. We aimed to identify risk factors for all-cause AGE, norovirus-associated vs non-norovirus AGE, and severe vs mild/moderate AGE among hospitalized adults. Methods: We enrolled 1029 AGE cases and 624 non-AGE controls from December 1, 2016, to November 30, 2019, at 5 Veterans Affairs Medical Centers. Patient interviews and medical chart abstractions were conducted, and participant stool samples were tested using the BioFire Gastrointestinal Panel. Severe AGE was defined as a modified Vesikari score of ≥11. Multivariate logistic regression was performed to assess associations between potential risk factors and outcomes; univariate analysis was conducted for norovirus-associated AGE due to limited sample size. Results: Among 1029 AGE cases, 551 (54%) had severe AGE and 44 (4%) were norovirus positive. Risk factors for all-cause AGE included immunosuppressive therapy (adjusted odds ratio [aOR], 5.6; 95% CI, 2.7–11.7), HIV infection (aOR, 3.9; 95% CI, 1.8–8.5), severe renal disease (aOR, 3.1; 95% CI, 1.8–5.2), and household contact with a person with AGE (aOR, 2.9; 95% CI, 1.3–6.7). Household (OR, 4.4; 95% CI, 1.6–12.0) and non-household contact (OR, 5.0; 95% CI, 2.2–11.5) with AGE was associated with norovirus-associated AGE. Norovirus positivity (aOR, 3.4; 95% CI, 1.3–8.8) was significantly associated with severe AGE. Conclusions: Patients with immunosuppressive therapy, HIV, and severe renal disease should be monitored for AGE and may benefit from targeted public health messaging regarding AGE prevention. These results may also direct future public health interventions, such as norovirus vaccines, to specific high-risk populations.

10 July 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
JNJoan Neyra
Joan Neyra
AKAnita K. Kambhampati
Anita K. Kambhampati
LCLaura E. Calderwood
Laura E. Calderwood
CRCandice Romero
Candice Romero
GSGiselle Soto
Giselle Soto
SMSara A. Mirza
Sara A. Mirza
While costs of norovirus acute gastroenteritis (AGE) to healthcare systems have been estimated, out-of-pocket and indirect costs incurred by households are not well documented in community settings, particularly in developing countries. We conducted active surveillance for AGE in two communities in Peru: Puerto Maldonado (October 2012–August 2015) and San Jeronimo (April 2015–April 2019). Norovirus AGE events with PCR-positive stool specimens were included. Data collected in follow-up interviews included event-related medical resource utilization, associated out-of-pocket costs, and indirect costs. There were 330 norovirus-associated AGE events among 3,438 participants from 685 households. Approximately 49% of norovirus events occurred among children <5 years of age and total cost to the household per episode was highest in this age group. Norovirus events cost a median of US $2.95 (IQR $1.04–7.85) in out-of-pocket costs and $12.58 (IQR $6.39–25.16) in indirect costs. Medication expenses accounted for 53% of out-of-pocket costs, and productivity losses accounted for 59% of the total financial burden on households. The frequency and associated costs of norovirus events to households in Peruvian communities support the need for prevention strategies including vaccines. Norovirus interventions targeting children <5 years of age and their households may have the greatest economic benefit.

8 July 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
LBLeslie Barclay
Leslie Barclay
MWMary Wikswo
Mary Wikswo
HWHelen Wall
Helen Wall
AKAnita K Kambhampati
Anita K Kambhampati
AMAnna M Montmayeur
Anna M Montmayeur
PCPreeti Chhabra
Preeti Chhabra
GII.4 noroviruses have been the leading cause of acute gastroenteritis outbreaks in the United States (U.S.) for the past decade. Recently, GII.17 viruses have emerged globally, raising concerns about changes in disease burden and potential replacement of GII.4 as the predominant strain. We characterized molecular and epidemiological features of U.S. GII.17 norovirus outbreaks from September 2021-August 2025 submitted to CaliciNet. Norovirus-positive outbreak samples were sequenced followed by RdRp and VP1 phylogenetic analyses. CaliciNet and National Outbreak Reporting System data were linked to compare GII.17 and GII.4 epidemiologic and clinical characteristics. Virus-like particles binding to gastric mucin and antibody blockade assays were conducted to assess antigenic variation among GII.17 variants. Among 1,412 outbreaks, GII.17 prevalence increased from 5.0% (2021-2022) to 74.8% (2024-2025). Compared with GII.4, GII.17 was more frequently reported with foodborne exposure (16.4% vs 9.6%), affected persons aged 10-49 years compared with other groups (31.1% vs 23.1%), and associated with slightly higher rates of vomiting (78.2% vs 72.2%), abdominal cramps (34.2% vs 30.1%), and fever (15.9% vs 10.9%). Phylogenetic analysis detected GII.17[P17] Romania-like (93.3%) followed by GII.17[P17] Kawasaki308-like strains (4.6%) and two novel tentative variants: Santa Clara (1.3%) and London (0.1%). Despite substitutions in key P2 antigenic sites, surrogate antibody neutralization remained conserved. These findings indicate a recent shift in norovirus genotype dominance in the U.S., likely driven by enhanced transmissibility or population susceptibility rather than increased virulence. Continued molecular surveillance is essential to monitor viral evolution and public health impact of norovirus.